Mark R. Hake

Mark R. Hake

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Ideanomics Could Be Worth Significantly More Based on Acquisitions

Ideanomics could be worth significantly more based on its acquisitions. IDEX stock could end up having a cash cow business with its Timios real estate title and escrow company.

5 Marijuana Stocks for the Conservative Investor

These five marijuana stocks are for careful, conservative investors. They each have safe financial traits for those who like to play it safe.

Ethereum May Become a Corporate Treasury Asset

Ethereum is likely to eventually become a corporate treasury asset. Ethereum will likely have higher appeal than Bitcoin given its wider transaction coverage and no supply cap.

Ocugen Could Still Be Undervalued If Its Covid-19 Vaccine Gets OK

Ocugen could still be undervalued if the FDA approves its Covid-19 vaccine. OCGN could be worth as much as $12.73 per share, 24% higher, using scenario and probability analysis.

5 Crypto-Related Stocks You Can Buy Instead of Cryptocurrencies

If you'd rather buy crypto-related stocks instead of cryptocurrencies, these five can give you exposure to the movement of cryptos.